- Home
- GBIO vs STRT Comparison
GBIO vs STRT Comparison
Compare GBIO & STRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- STRT
- Stock Information
- Founded
- GBIO 2016
- STRT 1908
- Country
- GBIO United States
- STRT United States
- Employees
- GBIO N/A
- STRT N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- STRT Auto Parts:O.E.M.
- Sector
- GBIO Health Care
- STRT Consumer Discretionary
- Exchange
- GBIO Nasdaq
- STRT Nasdaq
- Market Cap
- GBIO 29.5M
- STRT N/A
- IPO Year
- GBIO 2020
- STRT 1995
- Fundamental
- Price
- GBIO $5.77
- STRT $69.35
- Analyst Decision
- GBIO Buy
- STRT
- Analyst Count
- GBIO 4
- STRT 0
- Target Price
- GBIO $10.67
- STRT N/A
- AVG Volume (30 Days)
- GBIO 76.7K
- STRT 75.4K
- Earning Date
- GBIO 11-05-2025
- STRT 11-03-2025
- Dividend Yield
- GBIO N/A
- STRT N/A
- EPS Growth
- GBIO N/A
- STRT 12.53
- EPS
- GBIO N/A
- STRT 4.58
- Revenue
- GBIO $21,230,000.00
- STRT $565,066,000.00
- Revenue This Year
- GBIO N/A
- STRT $0.40
- Revenue Next Year
- GBIO N/A
- STRT $6.06
- P/E Ratio
- GBIO N/A
- STRT $14.97
- Revenue Growth
- GBIO 61.15
- STRT 5.08
- 52 Week Low
- GBIO $3.00
- STRT $31.57
- 52 Week High
- GBIO $29.10
- STRT $83.00
- Technical
- Relative Strength Index (RSI)
- GBIO 50.66
- STRT 54.03
- Support Level
- GBIO $5.51
- STRT $65.00
- Resistance Level
- GBIO $6.04
- STRT $71.54
- Average True Range (ATR)
- GBIO 0.32
- STRT 2.58
- MACD
- GBIO -0.10
- STRT 0.19
- Stochastic Oscillator
- GBIO 26.80
- STRT 73.80
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.